Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
Company Contact | |
Address: | 1495 Bonhill Road, Unit # 1 Mississauga MISSISSAUGA ON L5T 1M2 |
Tel: | N/A |
Website: | https://medxhealth.com |
IR: | See website |
Key People | ||
Stephen Lockyer Acting Chief Executive Officer, Director | Christopher H. Freeman Acting Chief Financial Officer, Corporate Secretary | Michael Druhan President - Dermatological Services and Products |
Business Overview |
MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use technology utilizing light and its remittance to view suspicious moles and lesions up to two millimeters (mm) beneath in a pain-free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology. |
Financial Overview |
For the fiscal year ended 31 December 2023, Medx Health Corp revenues decreased 11% to C$456K. Net loss decreased 11% to C$4.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Salaries and benefits, contractors decrease of 51% to C$587K (expense), Sales and market development decrease of 70% to C$233K (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $29.17M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.46M as of Dec 31, 2023 |
EBITDA (TTM): | -$2.97M as of Dec 31, 2023 |
Net annual income (TTM): | -$4.58M as of Dec 31, 2023 |
Free cash flow (TTM): | -$3.42M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $5.71M as of Dec 31, 2023 |
Shares outstanding: | 261,956,603 as of Feb 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |